Clinical Trial Update: A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement [Phase 4]

View source ↗

Summary

This Phase 4 trial reports on the long-term performance of SmartSet HV and SmartSet GHV bone cements used in primary total hip replacement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avascular Necrosis
• Congenital Hip Dysplasia
• Nonunion of Femoral Fractures
• Osteoarthritis
• Post-traumatic Arthritis
• Rheumatoid Arthritis
• Slipped Capital Femoral Epiphysis
• Traumatic Femoral Fractures

Drugs mentioned

• SmartSet GHV Bone Cement (bone cement (polymethyl methacrylate))
• SmartSet HV Bone Cement (bone cement (polymethyl methacrylate))

Snippet

Sponsor: DePuy International | Conditions: Rheumatoid Arthritis, Osteoarthritis | Phase 4 | Status: COMPLETED